TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01602458

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silicone Only Therapy (SOT)
Description: SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silicone Pressure Garment Therapy (SPGT)
Description: SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment.
Study: NCT03854981

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
Study: NCT01264003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sefazolin
Description: In prophylaxis
Study: NCT03854981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard preoperative care of bariatric surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard preoperative care of bariatric surgery
Study: NCT02307435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
Study: NCT03543020

Intervention type: RADIATION
Intervention: radiation therapy to brain
Description: OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
Study: NCT01092442

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Patients will have a yearly echocardiogram after enrollment in the study.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Patients will have a yearly echocardiogram after enrollment in the study.
Study: NCT00926705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Fentanyl
Description: Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
Study: NCT01657500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corneal donor storage in Optisol GS media solution
Description: Donor tissue is preserved in the Optisol media until ready for implantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life 4°C solution for cornea storage
Description: Donor cornea is stored in the Life 4°C media prior to implantation.
Study: NCT04103970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Activity and Pain Education (GAPE)
Description: GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement.
Study: NCT03123185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state
Study: NCT02218632

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactose-free diet
Description: standard diet
Study: NCT04325386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Sessions
Description: Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Education Session
Description: No Education Session
Study: NCT01666652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 µg TDENV-PIV with Alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 µg TDENV-PIV with AS03B1 adjuvant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffered saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 µg TDENV-PIV with Alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 µg TDENV-PIV with AS01E1 adjuvant
Study: NCT02218632

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Temporary oral galactose supplements
Description: galactose supplements in the range of physiological galactose production
Study: NCT04308798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical glove changing
Description: Changing surgical glove after draping and before cementation during total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical glove changing
Description: Changing surgical glove after draping and before cementation during total knee arthroplasty
Study: NCT01399099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embrace device
Description: Adhesive bandage/dressing intended to minimize scar formation.
Study: NCT02405858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
Study: NCT01695239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study: NCT02405858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
Study: NCT02739828

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Adalimumab
Study: NCT04341662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-MOTIVE intervention
Description: The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
Study: NCT04308798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical glove changing
Description: Changing surgical glove after draping and before cementation during total knee arthroplasty
Study: NCT02535923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Insomnia
Description: CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Description: Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
Study: NCT01093833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Continuous glucose monitor (BD CGM)
Description: Continuous glucose monitoring for 12-14 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI Glucose Analyzer
Description: Continuous glucose monitoring for 12-14 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Guardian CGM
Description: Continuous glucose monitoring for 12-14 hours
Study: NCT05600699

Intervention type: DEVICE
Intervention: Cardiac pacemaker and Select Secure lead
Description: model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA

Intervention type: DEVICE
Intervention: Cardiac pacemaker and Select Secure lead
Description: model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA

Intervention type: DEVICE
Intervention: Cardiac pacemaker and Select Secure lead
Description: model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
Study: NCT03388905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Life Vest Wearable defibrilator
Description: The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
Study: NCT02471027

Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy
Description: There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
Study: NCT05039996

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: education and relaxation program
Description: randomized controlled trial

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education and relaxation program
Description: randomized controlled trial
Study: NCT03512483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Atrial Fibrillation Clinic
Description: Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
Study: NCT00796328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Description: Up-down, biased coin design
Study: NCT01369368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.
Description: Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
Study: NCT03865251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Description: Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
Study: NCT03753503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercised three times a week in the 8-week HIIT program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Study: NCT03364686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biotin-Labeled Red Blood Cells
Description: We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
Study: NCT04623060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of Low-volume interval treadmill training and Resistance Training
Description: Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2.
Study: NCT00183391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
Study: NCT02636322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00649571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate Tablets (100 mg
Description: 100mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoxa Tablets 100 mg
Description: 100mg, single dose fasting
Study: NCT04744532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib (Phase 1 part)
Description: Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib (Phase 2 part)
Description: Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
Study: NCT03987607

Intervention type: DEVICE
Intervention: neuromuscular blockade monitoring
Description: Neuromuscular blockade monitoring via two different types of monitoring devices
Study: NCT00395512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets.
Study: NCT03847805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapulothoracic and glenohumeral stabilization exercises
Description: The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral stability exercises
Description: the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
Study: NCT01077895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CVVH
Description: CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Description: CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrafiltration
Description: ultra filtration is started at 100 mL/h and increased according to following protocol~* Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~* Vasopressor or inotrope medication dose is increased by \> 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~* When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV \> 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~* If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrafiltration control group
Description: ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
Study: NCT00803907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)